Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab
Gastric cancer (GC) represents one of the most fatal neoplasms in gastrointestinal oncology and affected patients can only hope for cure in limited disease. In a metastatic situation however, patients have a worse prognosis finally resulting in cancer-related death. Some improvements were made by us...
Main Authors: | Sebastian Schade, Ute Koenig, Ardian Mekolli, Jochen Gaedcke, Albrecht Neesse, Johanna Reinecke, Marius Brunner, Ali Seif Amir Hosseini, Julia Kitz, Philipp Stroebel, Joachim Lotz, Michael Ghadimi, Volker Ellenrieder, Alexander Koenig |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2022-02-01
|
Series: | Case Reports in Gastroenterology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/520057 |
Similar Items
-
Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
by: Alessandro D. Santin, et al.
Published: (2017-02-01) -
Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
by: Tong G, et al.
Published: (2020-04-01) -
Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
by: Silvia Pelligra, et al.
Published: (2020-05-01) -
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
by: Blair McNamara, et al.
Published: (2023-08-01) -
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
by: Joseph Tintelnot, et al.
Published: (2023-10-01)